Avoro Capital Advisors LLC Adaptimmune Therapeutics PLC Transaction History

Avoro Capital Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $6.96 Million - $12.9 Million	-2,024,400 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $5.89 Million - $8.82 Million	-1,525,600 Reduced 42.97%	2,024,400 $8.62 Million
Q4 2020 Feb 16, 2021	SELL	$4.0 - $9.2 $29.8 Million - $68.5 Million	-7,450,000 Reduced 67.73%	3,550,000 $19.1 Million
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $7.66 Million - $10.8 Million	1,000,000 Added 10.0%	11,000,000 $87.8 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $25.8 Million - $121 Million	10,000,000 New	10,000,000 $100 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.